Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCISE: Cetuximab vs Carboplatin/Paclitaxel with Radiotherapy in Advanced Head and Neck Cancer
NCT07441681Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2026
- Primary completion
- Nov 2035
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140, carboplatin, Paclitaxel Micelles for Injection in head and neck squamous cell carcinoma (HNSCC), sponsored by NRG Oncology. Started Jul 2026; status: recruiting.
02
Drugs
KL-140carboplatinPaclitaxel Micelles for Injection
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07441681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441681.